Cyclacel Pharmaceuticals (CYCC +40.4%) soars after saying that Phase II studies of it's lead...

|About: Cyclacel Pharmaceuticals, Inc. (CYCC)|By:, SA News Editor

Cyclacel Pharmaceuticals (CYCC +40.4%) soars after saying that Phase II studies of it's lead drug candidate Sapacitabine, a treatment for older patients with intermediate-2 or high-risk myelodysplastic syndrome, nearly doubled expected survival rates for elderly patients.